Halozyme Therapeutics (HALO) Tops Q2 EPS by 15c ; Offers Guidance
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $98.66 -2%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $0.91, $0.15 better than the analyst estimate of $0.76. Revenue for the quarter came in at $231 million versus the consensus estimate of $208.94 million.
GUIDANCE:
Halozyme Therapeutics sees FY2024 EPS of $3.65-$4.05, versus the consensus of $4.72. Halozyme Therapeutics sees FY2024 revenue of $0.93-1.01 billion, versus the consensus of $0.98 billion.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Movano (MOVE) Misses Q2 EPS by 195c
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Phillips 66, Marathon Merger Talks Collapsed - Semafor
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
